GORE® VIABIL® Biliary Endoprosthesis in the Treatment of Benign Biliary Strictures Secondary to Chronic Pancreatitis

Pancreatitis, Chronic Clinical Trial

— VIABILITY  

Official title:

Evaluation of the GORE® VIABIL® Biliary Endoprosthesis in the Treatment of Benign Biliary Strictures Secondary to Chronic Pancreatitis

Clinical Trial Details — Status: Suspended

Administrative data

• NCT number: NCT05820009
• Other study ID #: VBL 22-01
• Status: Suspended
• Phase: N/A
• Start date: February 1, 2024
• Est. completion date: August 1, 2028

Study information

• Verified date: January 2024
• Source: W.L.Gore & Associates
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will evaluate the safety and effectiveness of the GORE® VIABIL® Biliary Endoprosthesis in the treatment of benign biliary strictures secondary to Chronic Pancreatitis (CP).

Description:

A maximum of 15 clinical investigative sites across the U.S. will participate in this study. One hundred and thirty-three subjects are intended to be implanted with the GORE® VIABIL® Biliary Endoprosthesis in this study. Subjects will be evaluated at the time of device placement and will have follow-up visits at 1 week and 1, 3, 6, and 9 months during indwell; subjects will have the device removed at 10-12 months and have post removal follow-up visits at 1 week and 1, 3, 6, 12 and 24 months.

Recruitment information / eligibility

• Status: Suspended
• Enrollment: 133
• Est. completion date: August 1, 2028
• Est. primary completion date: August 1, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria

1. A diagnosis of chronic pancreatitis

2. Indication for ERCP with FCSEMS placement determined by one or more of the following:

1. Presence of a Bismuth type I BBS confirmed by imaging (e.g., cholangiography, Computed Tomography [CT], Magnetic Resonance Cholangiopancreatography [MRCP], etc.) collected = 60 days prior to the index procedure and an elevation of serum alkaline phosphatase (>2 times the upper limit of institutional reference range)

2. Presence of a symptomatic (e.g., jaundice, cholangitis, and/or choledocholithiasis) Bismuth type I BBS confirmed by imaging (e.g., cholangiography, CT, MRCP, etc.) collected = 60 days prior to the index procedure with an elevation of serum alkaline phosphatase (>2 times the upper limit of institutional reference range)

3. A planned exchange of multiple side-by-side plastic stents (whose combined diameters are = 20 Fr) that were previously placed for management of a Bismuth type I BBS secondary to chronic pancreatitis

3. Underlying stricture malignancy has been reasonably excluded (e.g., by any of the following techniques - biopsy, Endoscopic Ultrasound [EUS], Computed Tomography [CT], or Magnetic Resonance Imaging [MRI] with or without Magnetic Resonance Cholangiopancreatography [MRCP]) = 60 days prior to index procedure

4. = 18 years old at the time of informed consent signature

5. Male, infertile female, or woman of childbearing potential with a negative beta Human Chorionic Gonadotropin (hCG) pregnancy test within 7 days of the index procedure

6. Able and willing to provide written informed consent (or has a Legally Authorized Representative) to participate in the study prior to any study procedures

7. Willing and able to comply with the study procedures and follow-up requirements Exclusion Criteria

1. Concurrent participation in another interventional study that involves an investigational product being introduced to the body

2. A contraindication for endoscopic techniques

3. Life expectancy < 2 years

4. A history of malignant biliary or malignant pancreatic disease

5. Prior or existing biliary self-expanding metal stent (SEMS)

6. Prior or planned exchange of multiple side-by-side plastic stents whose combined diameters are greater than 20 Fr

7. Development of obstructive biliary symptoms associated with a present attack of acute pancreatitis

8. Any biliary stricture etiology other than chronic pancreatitis

9. Other therapeutic endoscopic procedures performed during the index or removal procedure that are not associated with bile duct stricture secondary to Chronic Pancreatitis including but not limited to planned Fine Needle Aspiration (FNA) or Fine Needle Biopsy (FNB) of the pancreas

10. Concomitant Bismuth type II-IV stricture

11. Inability for the guidewire to traverse the papillae and the stricture (e.g., as a result of surgically altered anatomy)

12. Inability to pass the endoscope to the papillae without the need for mechanical dilation

13. Known bile duct fistula or leak

14. Biliary stricture length > 100 mm (10 cm)

Related Conditions & MeSH terms

• Constriction, Pathologic
• Pancreatitis
• Pancreatitis, Chronic
• Stricture; Bile Duct

Intervention

Device:
• GORE® VIABIL® Biliary Endoprosthesis
Endoscopic treatment of benign biliary stricture secondary to Chronic Pancreatitis with the GORE® VIABIL® Biliary Endoprosthesis.
• GORE® VIABIL® Short Wire Biliary Endoprosthesis
Endoscopic treatment of benign biliary stricture secondary to Chronic Pancreatitis with GORE® VIABIL® Short Wire Biliary Endoprosthesis

Locations

Country	Name	City	State
United States	UNC School of Medicine	Chapel Hill	North Carolina
United States	Virginia Mason Medical Center	Seattle	Washington

Sponsors (1)

Lead Sponsor	Collaborator
W.L.Gore & Associates

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safe stent removal as reported by serious adverse event reporting	Ability to remove the Study Device endoscopically without stent removal-related serious adverse events (SAEs) as assessed from the time of Study Device removal to one month (30 days) post-Study Device removal.	At removal (10-12 months)
Secondary	Placement success as determined by imaging	Ability to deploy the Study Device in a satisfactory position across the biliary stricture.	Day 0
Secondary	Stent functionality as determined by adverse event reporting	Defined as freedom from Study Device-related reintervention during intended indwell	During indwell up to 12 months
Secondary	Migration as determined by imaging	Defined as movement of the Study Device such that the Study Device is no longer in a satisfactory position across the biliary stricture during intended indwell.	During indwell up to 12 months
Secondary	Removal success as determined by imaging	Defined as either ability to remove the Study Device endoscopically at scheduled Study Device removal without stent removal-related SAEs or spontaneous Study Device passage without the need for immediate re-stenting	At removal (10-12 months)
Secondary	Stricture resolution at stent removal as determined by imaging	Defined as freedom from recurrent stent placement at the end of indwell	At removal (10-12 months)
Secondary	Stricture recurrence as determined by adverse event reporting	Defined as any biliary stricture-related re-intervention from the removal procedure through 2 years post-Study Device removal.	From removal up to 24 months
Secondary	Device- or procedure-related SAEs as determined by serious adverse event reporting	Defined as Study Device- or procedure-related SAEs that occur during placement, indwell, or removal (including through 30 days post-removal).	Day 0-13 months (including through 30 days post-removal)
Secondary	Liver Function as determined by alkaline phosphatase, alanine aminotransferase, and aspartate aminotransferase levels	Including alkaline phosphatase (ALP, U/L), alanine aminotransferase (ALT, U/L), aspartate aminotransferase (AST, U/L) levels	Baseline, indwell follow-up visits (up to 12 months), at removal (10-12 months), and post-removal follow up visits (up to 24 months)
Secondary	Liver Function as determined by direct bilirubin, and total bilirubin	Including direct bilirubin (mg/dL), and total bilirubin (mg/dL) levels	Baseline, indwell follow-up visits (up to 12 months), at removal (10-12 months), and post-removal follow up visits (up to 24 months)